Cholesterol Remnants

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1		Francesco Angelico	--	2022	2023-03-03 11:22:34	\|
2	format correction	Dean Liu	-2 word(s)	2020	2023-03-10 02:05:58	\|

This entry is adapted from the peer-reviewed paper 10.3390/ijms24054268

Randomized clinical trials with statins and other lipid-lowering drugs have shown the presence of a “residual cardiovascular risk” in those treated to “target” for LDL-cholesterol. This risk is mainly associated to lipid components other than LDL and in particular to remnant cholesterol (RC) and to lipoproteins rich in triglycerides in fasting and non-fasting conditions. Remnant lipoproteins and inflammation, as well as LP (a), are causally related to risk of ACVD in individuals already treated with statin therapyremnant lipoproteins and inflammation, as well as LP (a), are causally related to risk of ACVD in individuals already treated with statin therapyremnant lipoproteins and inflammation, as well as LP (a), are causally related to risk of ACVD in individuals already treated with statin therapy.

remnant cholesterol triglyceride-rich lipoprotein residual cardiovascular risk

1. Introduction

Over the last few years, the importance of controlling the “residual risk”, in subjects who have reached the LDL cholesterol (LDL-C) “target”, during cholesterol-lowering therapy, has been emphasized ^[1]. In fact, the results of statin trials have demonstrated that even after maximal treatment with statins and/or lipid-lowering combination therapy, a significant residual cardiovascular risk often remains ^[2]. While in the past the residual risk was considered as the consequence of the still elevated LDL-C serum levels after statin treatment, recently, the concept of residual risk has been extended to the risk associated with known and modifiable but not completely corrected and correctable lipid and non-lipid risk factors (e.g., HDL-C and triglycerides (TG) levels, lipoprotein (a), abdominal adiposity, blood pressure, insulin resistance, smoking, fatty liver etc.) ^[3]^[4]. More recently, the concept of residual risk has been extended also to the risk associated with factors not yet fully elucidated (e.g., inflammation, oxidative stress, liver fibrosis, etc.).

Multiple lines of evidence suggest that triglyceride-rich lipoproteins (TGRLs) play a central role in residual cardiovascular risk. In particular, it has been suggested that remnant cholesterol (RC) levels are likely contributors to the residual risk in patients with very well controlled LDL-C levels on intensive lipid lowering therapy. RCs are probably the most important determinants of cardiovascular risk after LDL-C levels. In fact, plasma concentration of remnants appears to be related to cardiovascular risk independently of LDL-C.

Moreover, both LDL-TG and RCs, but not LDL-C are related to systemic low-grade inflammation and vascular damage ^[5]^[6] and it has been proposed that the TG content of LDL may be a marker of delayed remnant particle catabolism. Consistent with these observations, individuals with increased LDL-TG and RCs concentrations have also increased concentrations of inflammatory marker hs-CRP and white blood cell count ^[7], which may reflect an adverse impact of inflammation. Additionally, beyond residual cholesterol risk, the results of clinical trials also support the concept of residual inflammation risk. In fact, in both Prove It ^[8] and Improve IT ^[9] trials almost one-third of statin-treated patients had hs-CRP > 2 mg/L. Therefore, accumulating evidences from epidemiological and genetic studies, as well as randomized clinical trials, suggest that remnant lipoproteins and inflammation, as well as LP (a), are causally related to risk of ACVD in individuals already treated with statin therapy ^[10].

2. How to Measure Cholesterol Remnants

Accurate measurement of RCs is difficult due to the heterogeneity of lipoprotein composition, size and density, as well as to their rapid metabolization. RC measurement by separating lipoproteins with ultracentrifugation or polycrylamide gel electrophoresis is complex and is rarely performed in the clinical setting. Conceptually, RCs represent the non-HDL and non-LDL circulating cholesterol. In both clinical practice and epidemiology, and only in fasting conditions, it has been proposed to roughly calculate plasma RCs levels by subtracting HDL-C and LDL-C values from total cholesterol. Excluding severe hypertriglyceridemia, where Frieldwald formula ^[11] is inapplicable, RCs values are easily computable starting from routine laboratory values ^[11]. In absence of dosed LDL-C, considering the 1 to 5 ratio between cholesterol and triglyceride content in VLDL under fasting conditions, researchers can easily calculate RCs dividing serum triglycerides by 5. Recently, a new method for calculating fasting LDL-C has been proposed, which allows a more accurate estimate of the values than those derived from the Friedwald formula ^[11]. This method is useful in conditions of serum low LDL-C and high TG which are observed with increasing frequency because of the increasingly effectiveness of LDL-lowering therapies and the growing prevalence of obesity and metabolic syndrome (19). This new calculation method suggests applying a correction factor to VLDL C/TG ratio, which in the Friedwald formula is calculated as 1:5, based on the individual values of serum non-HDL C and TG ^[12].

In addition to calculation methods, RC can be directly measured using a variety of analytical methods including ultracentrifugation, nuclear magnetic resonance (NMR) spectroscopy, and by a direct automated assay. A quantitative method for assessing the concentration of RC in fasting conditions is based on the immunoseparation of remnant-like particles in serum using monoclonal antibodies to apo B-100 and apoA1 ^[13]. The measurement of RC derived from the exogenous pathway (i.e., chylomicron remnants) can be performed via ultracentrifugation or, indirectly, by measuring apoB-48. Recently, within the Copenhagen General Population Study, it has been demonstrated that directly measured RC identifies more accurately patients at higher risk of myocardial infarction, in comparison to calculated ones ^[14].

In non-fasting conditions, RC evaluation is more complex since remnants deriving from intestinal chylomicrons are added to VLDL remnants. In this condition, RCs are strongly correlated with TG serum levels which vary according to lipid meals composition and to fasting length since the last meal. In fact, after a fatty meal, apo-B48 levels, TGRLs-C and TG rapidly increase, while there is no postprandial increase in the apoB-100 and LDL-C values. For this reason, postprandial apoB-48 values could be used as a very sensitive marker of non-fasting triglyceridemia, using immunoturbidimetric and immunonephelometric assays commercially available on commonly used automated systems from several manufacturers ^[15].

RC serum levels vary little between fasting and postprandial periods. Therefore, even in non-fasting condition, RC levels can be accurately calculated by subtracting HDL-C and LDL-C from total cholesterol. To date, RCs in most studies have only been evaluated in fasting conditions and researchers have little information regarding RC and LRT concentration during the postprandial period. Both increase after a fatty meal, mostly in subjects with primary or secondary lipoprotein metabolism alterations and in those with insulin resistance. However, at the present, researchers do not yet have a standardized oral fatty meal test for the evaluation of lipid changes during the postprandial phase.

Finally, there is a strong urgency for the development of automated direct analysis methods given the importance of remnants evaluation in the definition of residual cardiovascular risk ^[15].

3. Cholesterol Remnants and Their Role in Atherogenesis

Remnant lipoproteins are cleared by the liver mainly via LDL receptor or penetrate arterial wall, thus contributing to the initiation and progression of atherosclerotic lesions. Unlike chylomicrons and VLDLs which do not penetrate the vessel wall due to their large size, and similarly to LDLs, LRTs remnants, due to the small size, easily pass through the arterial wall and are retained in the sub-endothelium, where they bind to the connective matrix and promote inflammation. Their presence stimulates the progression of smooth muscle cells and the proliferation of resident macrophages ^[16]^[17]. However, unlike LDLs, TGRLs are directly degraded by scavenger receptors in macrophages in the absence of oxidative modifications thus contributing to plaque formation and progression. RCs can also induce endothelial dysfunction, the production of adhesion molecules and platelet activation, as well as increase the expression of CD40 and metalloproteins ^[18]^[19]. Finally, high levels of non-fasting RCs can increase the expression of inflammatory interleukins and cytokines, increase the inflammatory response of monocytes and induce the appearance of a chronic low-grade inflammation, which, on the contrary, is not observed in the presence of high levels of LDL-C ^[6]^[20].

4. Cholesterol Remnants and Cardiovascular Events

Several studies examined the atherogenic role of RCs. Since 2001, a positive association was described, independent of traditional risk factors, between TGRLs-remnant levels and the ischemic heart disease prevalence in a sample of women from the Framingham Heart Study ^[21]. Subsequently, Fukuscima et al. ^[22] demonstrated that elevated TGRLs-C levels were a significant and independent risk factor for ischemic heart disease and type 2 diabetes mellitus.

However, it is in Denmark that the largest studies on the predictive role of TGRLs on cardiovascular events have been carried out. In a study conducted over 22 years on 90,000 Danish subjects, the progressive increases in non-fasting measured RC and LDL-C were similarly associated with the increased risk of ischemic heart disease and myocardial infarction; however, only RC levels were associated with all-cause mortality ^[23]^[24]. It was estimated that a 1 mmol/L (39 mg/dL) increase in RC in non-fasting conditions was shown to correspond to a 2.8-fold increased risk for coronary heart disease ^[23]^[24]. A subsequent study, also conducted in Denmark on a court of 5414 patients with ischemic heart disease, confirmed the association between calculated and/or measured non-fasting RC levels and all-cause mortality, while a similar association was not observed for LDL-C levels ^[4]. More recently, lowering RCs of 32 mg/dL and 81 mg/dL was estimated to reduce recurrent MACE by 20% and 50% respectively ^[25]. Finally, very recently, in a follow up study of 19,650 adults in the United States from the National Health and Nutrition Examination Survey (NHANES) (1999–2014), elevated RC levels were independently associated with cardiovascular mortality ^[26].

Similarly, in a series of patients with coronary heart disease treated with lipid-lowering therapies and reaching LDL-C values < 100 mg/dL, TGRL-C values predicted coronary events recurrence, suggesting RCs as a possible new target of “residual risk” ^[27]. Similar results were reported by Kugiyana C. et al. in 153 patients with coronary heart disease ^[28]. Moreover, in a TNT trial post-hoc analysis, fasting TGRLs-C values predicted cardiovascular events and 1 SD RC reduction by atorvastatin reduced cardiovascular events incidence similarly to that obtained with 1 SD LDL-C reduction ^[29].

The association between RCs and cardiovascular disease was confirmed in different ethnicities). In a study conducted in Japan, confirming the predictive role of CR levels on cardiovascular events recurrence in secondary prevention, RC values were used to increase the prognostic value of traditional risk factors, allowing the authors to better stratify patients’ cardiovascular risk ^[30]. In addition, no differences were observed in the predictive role between USA black (Jackson Heart Study) and white (Framingham Offspring Cohort Study) subjects ^[31]. In a Chinese community-based population, increased RC levels better associated with new-onset carotid plaque diagnosis in comparison to other conventional lipid parameters ^[32]. Finally, in ASCVD-free individuals from three landmark US cohorts—the Atherosclerosis Risk in Communities (ARIC) study, the Multi-Ethnic Study of Atherosclerosis (MESA), and the Coronary Artery Risk Development in Young Adults (CARDIA)—levels of RC were associated with ASCVD independently from traditional cardiovascular risk factors, such as LDL-C, and non-HDL-C or apo-B levels ^[33].

The good RCs performance for the stratification of cardiovascular risk in dysmetabolic patients was confirmed by several studies. The predictive role of RCs on CV events was confirmed in subjects with type 2 diabetes and chronic kidney disease ^[34]. Moreover, in a prospective observational cohort study including 798 unselected NAFLD patients with cardio-metabolic diseases, high RC levels were predictive of future CVD ^[35]. Similarly, in the PREDIMED study, in overweight or obese subjects at high cardiovascular risk, TG and RC serum levels, but not LDL-C, were associated with cardiovascular outcomes ^[36]. Recently, a retrospective registry of real-world patients treated with PCSK9 inhibitors demonstrated a positive effect on RCs and lipid residual risk beyond LDL-C reductions ^[37].

Recently, data from Copenhagen General Population Study suggested a stronger association of elevated RCs with peripheral artery disease, than that observed with coronary heart disease and ischemic stroke ^[38]. Data from the same population also showed that high RCs and triglyceridemia associate with cardiovascular and other non-neoplastic causes of death ^[39].

Interestingly, mixed results were reported using lowering triglycerides (and cholesterol remnants) drugs to reduce cardiovascular events. While the use of pemafibrate was not associated with cardiovascular benefits ^[40], icosapent ethyl, was found to be effective in reducing both triglycerides and cardiovascular disease incidence ^[41]. In addition, other large trials, which used different formulations of omega-3 fatty acids, did not report significant cardiovascular risk reduction ^[42]. Some authors hypotizes a putative anti-inflammatory effect of icosapent ethyl. While the ANCHOR study showed a reduction of inflammatory markers in patients with decompensated diabetes ^[43], data from the REDUCE-IT did not confirm this finding ^[44]. A wide debate on the causes of these contrasting findings is still ongoing ^[45].

References

Vanuzzo, D. The epidemiological concept of residual risk. Intern. Emerg. Med. 2011, 6 (Suppl. 1), 45–51.
Ferrari, R.; Catapano, A.L. Residual cardiovascular risk. Eur. Heart J. Suppl. 2016, 18, C1.
Lawler, P.R.; Akinkuolie, A.O.; Chu, A.Y.; Shah, S.H.; Kraus, W.E.; Craig, D.; Padmanabhan, L.; Glynn, R.J.; Ridker, P.M.; Chasman, D.I.; et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. J. Am. Heart Assoc. 2017, 6, e005549.
Jepsen, A.M.; Langsted, A.; Varbo, A.; Bang, L.E.; Kamstrup, P.R.; Nordestgaard, B.G. Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease. Clin. Chem. 2016, 62, 593–604.
März, W.; Scharnagl, H.; Winkler, K.; Tiran, A.; Nauck, M.; Boehm, B.O.; Winkelmann, B.R. Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: The Ludwigshafen Risk and Cardiovascular Health study. Circulation 2004, 110, 3068–3074.
Varbo, A.; Benn, M.; Tybjærg-Hansen, A.; Nordestgaard, B.G. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013, 128, 1298–1309.
Saeed, A.; Feofanova, E.V.; Yu, B.; Sun, W.; Virani, S.S.; Nambi, V.; Coresh, J.; Guild, C.S.; Boerwinkle, E.; Ballantyne, C.M.; et al. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J. Am. Coll. Cardiol. 2018, 72, 156–169.
Cannon, C.P.; Braunwald, E.; McCabe, C.H.; Rader, D.J.; Rouleau, J.L.; Belder, R.; Joyal, S.V.; Hill, K.A.; Pfeffer, M.A.; Skene, A.M.; et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004, 350, 1495–1504.
Cannon, C.P.; Blazing, M.A.; Giugliano, R.P.; McCagg, A.; White, J.A.; Theroux, P.; Darius, H.; Lewis, B.S.; Ophuis, T.O.; Jukema, J.W.; et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N. Engl. J. Med. 2015, 372, 2387–2397.
Hoogeveen, R.C.; Ballantyne, C.M. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation. Clin. Chem. 2021, 67, 143–153.
Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972, 18, 499–502.
Martin, S.S.; Blaha, M.J.; Elshazly, M.B.; Toth, P.P.; Kwiterovich, P.O.; Blumenthal, R.S.; Jones, S.R. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA 2013, 310, 2061–2068.
Nakada, Y.; Kurosawa, H.; Tohyama, J.; Inoue, Y.; Ikewaki, K. Increased remnant lipoprotein in patients with coronary artery disease--evaluation utilizing a newly developed remnant assay, remnant lipoproteins cholesterol homogenous assay (RemL-C). J. Atheroscler. Thromb. 2007, 14, 56–64.
Varbo, A.; Nordestgaard, B.G. Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction. Eur. Heart J. 2021, 42, 4833–4843.
Langlois, M.R.; Chapman, M.J.; Cobbaert, C.; Mora, S.; Remaley, A.T.; Ros, E.; Watts, G.F.; Borén, J.; Baum, H.; Bruckert, E.; et al. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clin. Chem. 2018, 64, 1006–1033.
Chapman, M.J.; Ginsberg, H.N.; Amarenco, P.; Andreotti, F.; Borén, J.; Catapano, A.L.; Descamps, O.S.; Fisher, E.; Kovanen, P.T.; Kuivenhoven, J.A.; et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management. Eur. Heart J. 2011, 32, 1345–1361.
Nordestgaard, B.G.; Wootton, R.; Lewis, B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 534–542.
Bernelot Moens, S.J.; Verweij, S.L.; Schnitzler, J.G.; Stiekema, L.C.A.; Bos, M.; Langsted, A.; Kuijk, C.; Bekkering, S.; Voermans, C.; Verberne, H.J.; et al. Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans. Arterioscler. Thromb. Vasc. Biol. 2017, 37, 969–975.
Doi, H.; Kugiyama, K.; Oka, H.; Sugiyama, S.; Ogata, N.; Koide, S.I.; Nakamura, S.I.; Yasue, H. Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism. Circulation 2000, 102, 670–676.
Wang, Y.I.; Bettaieb, A.; Sun, C.; DeVerse, J.S.; Radecke, C.E.; Mathew, S.; Edwards, C.M.; Haj, F.G.; Passerini, A.G.; Simon, S.I. Triglyceride-rich lipoprotein modulates endothelial vascular cell adhesion molecule (VCAM)-1 expression via differential regulation of endoplasmic reticulum stress. PLoS ONE 2013, 8, e78322.
McNamara, J.R.; Shah, P.K.; Nakajima, K.; Cupples, L.A.; Wilson, P.W.; Ordovas, J.M.; Schaefer, E.J. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: Results from the Framingham Heart Study. Atherosclerosis 2001, 154, 229–236.
Fukushima, H.; Sugiyama, S.; Honda, O.; Koide, S.; Nakamura, S.; Sakamoto, T.; Yoshimura, M.; Ogawa, H.; Fujioka, D.; Kugiyama, K. Prognostic value of remnant-like lipoprotein particle levels in patients with coronary artery disease and type II diabetes mellitus. J. Am. Coll. Cardiol. 2004, 43, 2219–2224.
Varbo, A.; Benn, M.; Tybjærg-Hansen, A.; Jørgensen, A.B.; Frikke-Schmidt, R.; Nordestgaard, B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 2013, 61, 427–436.
Varbo, A.; Freiberg, J.J.; Nordestgaard, B.G. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. Clin. Chem. 2015, 61, 533–543.
Langsted, A.; Madsen, C.M.; Nordestgaard, B.G. Contribution of remnant cholesterol to cardiovascular risk. J. Intern. Med. 2020, 288, 116–127.
Zhang, K.; Qi, X.; Zhu, F.; Dong, Q.; Gou, Z.; Wang, F.; Xiao, L.; Li, M.; Chen, L.; Wang, Y.; et al. Remnant cholesterol is associated with cardiovascular mortality. Front. Cardiovasc. Med. 2022, 9, 984711.
Kugiyama, K.; Doi, H.; Takazoe, K.; Kawano, H.; Soejima, H.; Mizuno, Y.; Tsunoda, R.; Sakamoto, T.; Nakano, T.; Nakajima, K.; et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999, 99, 2858–2860.
Nakamura, T.; Obata, J.E.; Hirano, M.; Kitta, Y.; Fujioka, D.; Saito, Y.; Kawabata, K.; Watanabe, K.; Watanabe, Y.; Mishina, H.; et al. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals. Atherosclerosis 2011, 218, 163–167.
Vallejo-Vaz, A.J.; Fayyad, R.; Boekholdt, S.M.; Hovingh, G.K.; Kastelein, J.J.; Melamed, S.; Barter, P.; Waters, D.D.; Ray, K.K. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation 2018, 138, 770–781.
Nguyen, S.V.; Nakamura, T.; Kugiyama, K. High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome. Circ. J. 2014, 78, 2492–2500.
Joshi, P.H.; Khokhar, A.A.; Massaro, J.M.; Lirette, S.T.; Griswold, M.E.; Martin, S.S.; Blaha, M.J.; Kulkarni, K.R.; Correa, A.; D’Agostino, R.B.; et al. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. J. Am. Heart Assoc. 2016, 5, e002765.
Liu, B.; Fan, F.; Zheng, B.; Yang, Y.; Jia, J.; Sun, P.; Jiang, Y.; Li, K.; Liu, J.; Chen, C.; et al. Association of remnant cholesterol and lipid parameters with new-onset carotid plaque in Chinese population. Front. Cardiovasc. Med. 2022, 9, 903390.
Quispe, R.; Martin, S.S.; Michos, E.D.; Lamba, I.; Blumenthal, R.S.; Saeed, A.; Lima, J.; Puri, R.; Nomura, S.; Tsai, M.; et al. Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: A primary prevention study. Eur. Heart J. 2021, 42, 4324–4332.
Nguyen, S.V.; Nakamura, T.; Uematsu, M.; Fujioka, D.; Watanabe, K.; Watanabe, Y.; Obata, J.E.; Nakamura, K.; Kugiyama, K. Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease. J. Cardiol. 2017, 69, 529–535.
Pastori, D.; Baratta, F.; Novo, M.; Cocomello, N.; Violi, F.; Angelico, F.; Del Ben, M. Remnant Lipoprotein Cholesterol and Cardiovascular and Cerebrovascular Events in Patients with Non-Alcoholic Fatty Liver Disease. J. Clin. Med. 2018, 7, 378.
Castañer, O.; Pintó, X.; Subirana, I.; Amor, A.J.; Ros, E.; Hernáez, Á.; Martínez-González, M.; Corella, D.; Salas-Salvadó, J.; Estruch, R.; et al. Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease. J. Am. Coll. Cardiol. 2020, 76, 2712–2724.
Cordero, A.; Fernández Olmo, M.R.; Cortez Quiroga, G.A.; Romero-Menor, C.; Fácila, L.; Seijas-Amigo, J.; Rondán Murillo, J.; Sandin, M.; Rodríguez-Mañero, M.; Bello Mora, M.C.; et al. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry. Eur. J. Clin. Investig. 2022, 52, e13863.
Wadström, B.N.; Wulff, A.B.; Pedersen, K.M.; Jensen, G.B.; Nordestgaard, B.G. Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: A cohort-based study. Eur. Heart J. 2022, 43, 3258–3269.
Wadström, B.N.; Pedersen, K.M.; Wulff, A.B.; Nordestgaard, B.G. Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality. Eur. Heart J. 2023.
Das Pradhan, A.; Glynn, R.J.; Fruchart, J.C.; MacFadyen, J.G.; Zaharris, E.S.; Everett, B.M.; Campbell, S.E.; Oshima, R.; Amarenco, P.; Blom, D.J.; et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N. Engl. J. Med. 2022, 387, 1923–1934.
Bhatt, D.L.; Steg, P.G.; Miller, M.; Brinton, E.A.; Jacobson, T.A.; Ketchum, S.B.; Doyle, R.T.; Juliano, R.A.; Jiao, L.; Granowitz, C.; et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N. Engl. J. Med. 2019, 380, 11–22.
Nicholls, S.J.; Lincoff, A.M.; Garcia, M.; Bash, D.; Ballantyne, C.M.; Barter, P.J.; Davidson, M.H.; Kastelein, J.J.P.; Koenig, W.; McGuire, D.K.; et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020, 324, 2268–2280.
Brinton, E.A.; Ballantyne, C.M.; Bays, H.E.; Kastelein, J.J.; Braeckman, R.A.; Soni, P.N. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: The ANCHOR study. Cardiovasc. Diabetol. 2013, 12, 100.
Ridker, P.M.; Rifai, N.; MacFadyen, J.; Glynn, R.J.; Jiao, L.; Steg, P.G.; Miller, M.; Brinton, E.A.; Jacobson, T.A.; Tardif, J.C.; et al. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation 2022, 146, 372–379.
Sherratt, S.C.R.; Libby, P.; Budoff, M.J.; Bhatt, D.L.; Mason, R.P. Role of Omega-3 Fatty Acids in Cardiovascular Disease: The Debate Continues. Curr. Atheroscler. Rep. 2023, 25, 1–17.

© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Medicine, General & Internal

Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

Francesco Baratta

Nicholas Cocomello

Mattia Coronati

Domenico Ferro

Daniele Pastori

Francesco Angelico

Maria Del Ben

View Times: 328

Update Date: 10 Mar 2023

Table of Contents

Video Upload Options

Confirm